Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
NUFYMCO BLA has been approved by the USFDA
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated
